Clinical activity and safety of the RET inhibitor pralsetinib in patients with R
- This topic has 0 replies, 1 voice, and was last updated 2 years, 11 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial.
https://meetinglibrary.asco.org/record/197581/abstract
Viewing 1 post (of 1 total)
- The forum ‘New Developments’ is closed to new topics and replies.